Compare stocks

Saniona AB is a biopharmaceutical company based in Sweden, focusing on the discovery and development of treatments for rare diseases of the central nervous system. Its core business involves the research and development of ion channel modulators, which are pivotal in influencing cellular activity and treating neurological disorders. Saniona's pipeline includes product candidates such as Tesomet for rare eating disorders and SAN711 for neuropathic pain disorders. The company leverages its proprietary ion channel drug discovery platform to enhance its development capabilities. Saniona's strategic approach is distinguished by its focus on niche medical conditions with high unmet needs, positioning itself uniquely within the pharmaceutical industry. Sources: Saniona official website and public disclosures.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.